BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2022.
Corporate Update
“In 2022, we had multiple interactions with the FDA regarding the regulatory path forward for our lead compound, roluperidone. After submitting an NDA for roluperidone to the FDA in August, we received a Refuse to File letter (RTF) in the fall, which was upheld following another meeting with the FDA. We remain committed to developing roluperidone as a potentially transformative treatment for those patients with negative symptoms of schizophrenia and we anticipate further discussion with the FDA over the coming months,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.
Roluperidone
Fourth Quarter and Year End Financial Results
Conference Call Information:
The live conference call will begin this morning at 8:30 a.m. ET and may be accessed here and on the Company’s website under Events and Presentations.
The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), for negative symptoms of schizophrenia, and MIN-301, for Parkinson’s disease. For more information, please visit our website.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include, but are not limited to, statements herein with respect to the clinical and therapeutic potential of roluperidone (MIN-101); and the expectations regarding continued conversation with the FDA with respect to roluperidone and the timing thereof. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the FDA or equivalent foreign regulatory agencies and for which indications; whether we will be able to continue the discussion with the FDA regarding our NDA submission for roluperidone and the outcome thereof; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations and corporate objectives on terms acceptable to us; general economic conditions; and other factors that are described under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 8, 2023. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
Contact:
Investor inquiries:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media inquiries:
Helen Shik
Principal
Shik Communications LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
CONDENSED CONSOLIDATED BALANCE SHEET DATA | |||||||
(in thousands) | |||||||
December 31, 2022 | December 31, 2021 | ||||||
ASSETS | |||||||
Current Assets: | |||||||
Cash and cash equivalents | $ | 36,094 | $ | 60,755 | |||
Restricted cash | 100 | 100 | |||||
Refundable regulatory fee | 3,117 | - | |||||
Prepaid expenses and other current assets | 848 | 1,346 | |||||
Total current assets | 40,159 | 62,201 | |||||
Equipment & capitalized software, net | 59 | 52 | |||||
Goodwill | 14,869 | 14,869 | |||||
Total Assets | $ | 55,087 | $ | 77,122 | |||
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | |||||||
Current Liabilities: | |||||||
Accounts payable | $ | 969 | $ | 1,853 | |||
Accrued expenses and other current liabilities | 408 | 966 | |||||
Total current liabilities | 1,377 | 2,819 | |||||
Long-Term Liabilities: | |||||||
Liability related to the sale of future royalties | 73,734 | 66,327 | |||||
Total liabilities | 75,111 | 69,146 | |||||
Stockholders' (Deficit) Equity: | |||||||
Common stock | 1 | 1 | |||||
Additional paid-in capital | 346,785 | 342,676 | |||||
Accumulated deficit | (366,810 | ) | (334,701 | ) | |||
Total stockholders' (deficit) equity | (20,024 | ) | 7,976 | ||||
Total Liabilities and Stockholders' (Deficit) Equity | $ | 55,087 | $ | 77,122 | |||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
Three Months Ended December 31, (in thousands, except per share amounts) | Twelve Months Ended December 31 (in thousands, except per share amounts) | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Operating expenses: | |||||||||||||||
Research and development | $ | 3,190 | $ | 18,746 | $ | 14,649 | $ | 32,039 | |||||||
General and administrative | 1,880 | 2,631 | 10,582 | 13,327 | |||||||||||
Total operating expenses | 5,070 | 21,377 | 25,231 | 45,366 | |||||||||||
Loss from operations | (5,070 | ) | (21,377 | ) | (25,231 | ) | (45,366 | ) | |||||||
Foreign exchange loss | (28 | ) | (4 | ) | (28 | ) | (33 | ) | |||||||
Investment income | 297 | 4 | 557 | 17 | |||||||||||
Non-cash interest expense for the sale of future royalties | (1,925 | ) | (1,733 | ) | (7,407 | ) | (6,327 | ) | |||||||
Loss before income taxes | (6,726 | ) | (23,110 | ) | (32,109 | ) | (51,709 | ) | |||||||
Benefit for income taxes | - | 1,803 | - | 1,803 | |||||||||||
Net loss | (6,726 | ) | (21,307 | ) | (32,109 | ) | (49,906 | ) | |||||||
Net loss per share, basic and diluted | $ | (1.26 | ) | $ | (3.99 | ) | $ | (6.01 | ) | $ | (9.35 | ) | |||
Weighted average shares outstanding, basic and diluted | 5,340 | 5,340 | 5,340 | 5,340 |
Last Trade: | US$2.58 |
Daily Change: | -0.08 -3.14 |
Daily Volume: | 5,805 |
Market Cap: | US$18.030M |
August 06, 2024 May 01, 2024 February 22, 2024 November 07, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB